Cellular ADMA: Regulation and action

Pharmacological Research

Volumn 60, Issue 6, 2009, Pages 448-460

  Teerlink, Tom ^a   Luo, Zaiming ^b   Palm, Fredrik ^b   Wilcox, Christopher S ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Kidney and Vascular Health Center   (United States)

Author keywords

Cardiovascular disease; Cationic amino acid (CAA); Cationic amino acid transporter (CAT); Chronic kidney disease (CKD); Hypertension; Nitric oxide synthase (NOS); Protein arginine methyl transferase (PRMT); Reactive oxygen species and oxidative stress

Indexed keywords

AMINO ACID TRANSPORTER; ARGININE; DIMETHYLARGININASE; ESTROGEN; HOMOCYSTEINE; INSULIN; INTERLEUKIN 1BETA; METFORMIN; MICRORNA; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE; PROTEIN ARGININE METHYLTRANSFERASE; REPAGLINIDE; TELMISARTAN; TUMOR NECROSIS FACTOR ALPHA;

AMINO ACID METABOLISM; CARDIOVASCULAR DISEASE; CELLULAR DISTRIBUTION; CHRONIC KIDNEY DISEASE; CYTOKINE PRODUCTION; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; ENDOTOXEMIA; EXTRACELLULAR FLUID; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; GLYCEMIC CONTROL; HEART FAILURE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; KIDNEY FAILURE; KIDNEY PLASMA FLOW; KIDNEY POLYCYSTIC DISEASE; KIDNEY TUBULE ABSORPTION; MEMBRANE TRANSPORT; MULTIPLE ORGAN FAILURE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN HYDROLYSIS; PROTEIN TRANSPORT; REVIEW; STARVATION; TISSUE REGENERATION; TISSUE REPAIR; UREMIA;

ANIMALS; ARGININE; CARDIOVASCULAR DISEASES; ENDOTHELIAL CELLS; HUMANS; NITRIC OXIDE SYNTHASE; SIGNAL TRANSDUCTION;

EID: 70350048649     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2009.08.002     Document Type: Review

References (158)

1. G-dimethyl-l-arginine to l-citrulline in rats. Biochem Biophys Res Commun 148 (1987) 671-677
2. Vallance P., Leone A., Calver A., Collier J., and Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 20 (1992) S60-S62
3. Ueda S., Kato S., Matsuoka H., Kimoto M., Okuda S., Morimatsu M., et al. Regulation of cytokine induced nitric oxide synthasis by asymmetric dimethylarginine. Circ Res 92 (2003) 226-233
4. Baylis C. Arginine, arginine analogs and nitric oxide production in chronic kidney disease. Nat Clin Pract Nephrol 2 (2006) 209-220
5. Welch W.J., and Wilcox C.S. Macula densa arginine delivery and uptake in the rat regulates glomerular capillary pressure: effects of salt intake. J Clin Invest 100 (1997) 2235-2242
6. Vallance P., Leone A., Calver A., Collier J., and Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339 (1992) 572-575
7. Zoccali C. Traditional and emerging cardiovascular and renal risk factors: an epidemiologic perspective. Kidney Int 70 (2006) 26-33
8. Zoccali C. ADMA: a critical cardio-renal link in heart failure?. Eur J Clin Invest 33 (2003) 361-362
9. Zoccali C., Bode-Boger S.M., Mallamaci F., Benedetto F., Tripepi G., Malatino L.S., et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358 (2001) 2113-2117
10. Boger RH, Maas R, Schulze F, Schwedhelm E. Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality-an update on patient populations with a wide range of cardiovascular risk. Pharmacol Res; in press.
11. Boger R.H., Sullivan L.M., Schwedhelm E., Wang T.J., Maas R., Benjamin E.J., et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 119 (2009) 1592-1600
12. Palm F., Onozato M.L., Luo Z., and Wilcox C.S. Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. Am J Physiol Heart Circ Physiol 293 (2007) H3227-H3245
13. Wilcox C.S. Oxidative stress and nitric oxide deficiency in the kidney: a critical link to hypertension?. Am J Physiol Regul Integr Comp Physiol 289 (2005) R913-R935
14. Vallance P., and Leiper J. Asymmetric dimethylarginine and kidney disease-marker or mediator?. J Am Soc Nephrol 16 (2005) 2254-2256
15. Cynober L.A. Plasma amino acid levels with a note on membrane transport: characteristics, regulation, and metabolic significance. Nutrition 18 (2002) 761-766
16. Mann G.E., Yudilevich D.L., and Sobrevia L. Regulation of amino acid and glucose transporters in endothelial and smooth muscle cells. Physiol Rev 83 (2003) 183-252
17. Christensen H.N. Organic ion transport during seven decades. The amino acids. Biochim Biophys Acta 779 (1984) 255-269
18. White M.F. The transport of cationic amino acids across the plasma membrane of mammalian cells. Biochim Biophys Acta 822 (1985) 355-374
19. Deves R., and Boyd C.A.R. Transporters for cationic amino acids in animal cells: discovery, structure, and function. Physiol Rev 78 (1998) 487-545
20. Brunini T.M., Mendes-Ribeiro A.C., Ellory J.C., and Mann G.E. Platelet nitric oxide synthesis in uremia and malnutrition: a role for l-arginine supplementation in vascular protection?. Cardiovasc Res 73 (2007) 359-367
21. Mendes Ribeiro A.C., Brunini T.M., Ellory J.C., and Mann G.E. Abnormalities in l-arginine transport and nitric oxide biosynthesis in chronic renal and heart failure. Cardiovasc Res 49 (2001) 697-712
22. Wagner C.A., Lang F., and Broer S. Function and structure of heterodimeric amino acid transporters. Am J Physiol Cell Physiol 281 (2001) C1077-C1093
23. Hosokawa H., Sawamura T., Kobayashi S., Ninomiya H., Miwa S., and Masaki T. Cloning and characterization of a brain-specific cationic amino acid transporter. J Biol Chem 272 (1997) 8717-8722
24. Closs E.I., Boissel J.P., Habermeier A., and Rotmann A. Structure and function of cationic amino acid transporters (CATs). J Membr Biol 213 (2006) 67-77
25. Closs E.I., Basha F.Z., Habermeier A., and Forstermann U. Interference of l-arginine analogues with l-arginine transport mediated by the y+ carrier hCAT-2B. Nitric Oxide: Biol Chem 1 (1997) 65-73
26. Closs E.I., Albritton L.M., Kim J.W., and Cunningham J.M. Identification of a low affinity, high capacity transporter of cationic amino acids in mouse liver. J Biol Chem 268 (1993) 7538-7544
27. Kitiyakara C., Chabrashvili T., Jose P., Welch W.J., and Wilcox C.S. Effects of dietary salt intake on plasma arginine. Am J Physiol 280 (2001) R1069-R1075
28. Chin-Dusting J.P., Willems L., and Kaye D.M. l-arginine transporters in cardiovascular disease: a novel therapeutic target. Pharmacol Ther 116 (2007) 428-436
29. Gornik H.L., and Creager M.A. Arginine and endothelial and vascular health. J Nutr 134 (2004) 2880S-2887S
30. Tsikas D., Boger R.H., Sandmann J., Bode-Boger S.M., and Frolich J.C. Endogenous nitric oxide synthase inhibitors are responsible for the l-arginine paradox. FEBS Lett 478 (2000) 1-3
31. Boger R.H. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "l-arginine paradox" and acts as a novel cardiovascular risk factor. J Nutr 134 (2004) 2842S-2847S
32. McDonald K.K., Zharikov S., Block E.R., and Kilberg M.S. A caveolar complex between the cationic amino acid transporter 1 and endothelial nitric-oxide synthase may explain the "arginine paradox". J Biol Chem 272 (1997) 31213-31216
33. Hardy T.A., and May J.M. Coordinate regulation of l-arginine uptake and nitric oxide synthase activity in cultured endothelial cells. Free Radic Biol Med 32 (2002) 122-131
34. Smulders R.A., Aarsen M., Teerlink T., de Vries P.M.J.M., van Kamp G.J., Donker A.J.M., et al. Haemodynamic and biochemical responses to l-arginine and l-lysine infusions in normal subjects: l-arginine-induced vasodilation cannot be explained by non-specific effects of cationic amino acids. Clin Sci 92 (1997) 367-374
35. Prins H.A., Houdijk A.P., Wiezer M.J., Teerlink T., Van Lambalgen A.A., Thijs L.G., et al. The effect of mild endotoxemia during low arginine plasma levels on organ blood flow in rats. Crit Care Med 28 (2000) 1991-1997
36. Kielstein J.T., Impraim B., Simmel S., Bode-Böger S.M., Tsikas D., Frölich J.C., et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 109 (2004) 172-177
37. Teerlink T., Nijveldt R.J., de Jong S., and Van Leeuwen P.A. Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem 303 (2002) 131-137
38. Ogawa T., Kimoto M., and Sasaoka K. Purification and properties of a new enzyme, NG,NG-dimethylarginine dimethylaminohydrolase, from rat kidney. J Biol Chem 264 (1989) 10205-10209
39. Wang J., Sim A.S., Wang X.L., and Wilcken D.E. l-arginine regulates asymmetric dimethylarginine metabolism by inhibiting dimethylarginine dimethylaminohydrolase activity in hepatic (HepG2) cells. Cell Mol Life Sci 63 (2006) 2838-2846
40. Wilcken D.E., Sim A.S., Wang J., and Wang X.L. Asymmetric dimethylarginine (ADMA) in vascular, renal and hepatic disease and the regulatory role of l-arginine on its metabolism. Mol Genet Metab 91 (2007) 309-317
41. Sessa W.C., Hecker M., Mitchell J.A., and Vane J.R. The metabolism of l-arginine and its significance for the biosynthesis of endothelium-derived relaxing factor: l-glutamine inhibits the generation of l-arginine by cultured endothelial cells. Proc Natl Acad Sci USA 87 (1990) 8607-8611
42. Arnal J.F., Munzel T., Venema R.C., James N.L., Bai C., and Mitch W.E. Interactions between l-arginine and l-glutamine change endothelial NO production. An effect independent of NO synthase substrate availability. J Clin Invest 95 (1995) 2565-2572
43. Wu G., and Morris Jr. S.M. Arginine metabolism: nitric oxide and beyond. Biochem J 336 (1998) 1-17
44. Brosnan M.E., and Brosnan J.T. Renal arginine metabolism. J Nutr 134 (2004) 2791S-2795S
45. Tizianello A., De F.G., Garibotto G., Gurreri G., and Robaudo C. Renal metabolism of amino acids and ammonia in subjects with normal renal function and in patients with chronic renal insufficiency. J Clin Invest 65 (1980) 1162-1173
46. Kakoki M., Wang W., and Mattson D.L. Cationic amino acid transport in the renal medulla and blood pressure regulation. Hypertension 39 (2002) 287-292
47. Deng X., Welch W.J., and Wilcox C.S. Renal vasodilation with l-arginine: effects of dietary salt. Hypertension 26 (1995) 256-262
48. Kielstein J.T., Bode-Böger S.M., Frölich J.C., Ritz E., Haller H., and Fliser D. Asymmetric dimethylarginine, blood pressure and renal perfusion in elderly subjects. Circulation 107 (2003) 1891-1895
49. Teerlink T. ADMA metabolism and clearance. Vasc Med 10 Suppl. 1 (2005) S73-S81
50. Ellger B., Richir M.C., Van Leeuwen P.A., Debaveye Y., Langouche L., Vanhorebeek I., et al. Glycemic control modulates arginine and asymmetrical-dimethylarginine levels during critical illness by preserving dimethylarginine-dimethylaminohydrolase activity. Endocrinology 149 (2008) 3148-3157
51. Onozato M.L., Tojo A., Leiper J., Fujita T., Palm F., and Wilcox C.S. Expression of DDAH and PRMT isoforms in the diabetic rat kidney; effects of angiotensin II receptor blockers. Diabetes 57 (2008) 172-180
52. Al Banchaabouchi M., Marescau B., Possemiers I., D'Hooge R., Levillain O., and De Deyn P.P. NG, NG-dimethylarginine and NG, NG-dimethylarginine in renal insufficiency. Pflugers Arch 439 (2000) 524-531
53. Nijveldt R.J., van Leeuwen P.A.M., van Guldener C., Stehouwer C.D.A., Rauwerda J.A., and Teerlink T. Net renal extraction of asymmetrical (ADMA) and symmetrical (SMDA) dimethylarginine in fasting humans. Nephrol Dial Transplant 17 (2002) 1999-2002
54. Nijveldt R.J., Teerlink T., van Guldener C., Prins H.A., van Lambalgen A.A., Stehouwer C.D.A., et al. Handling of asymmetrical dimethylarginine and symmetrical dimethylarginine by the rat kidney under basal conditions and during endotoxaemia. Nephrol Dial Transplant 18 (2003) 2542-2550
55. Achan V., Broadhead M., Malaki M., Whitley G., Leiper J., MacAllister R., et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 23 (2003) 1455-1459
56. Teerlink T. HPLC analysis of ADMA and other methylated l-arginine analogs in biological fluids. J Chromatogr B Analyt Technol Biomed Life Sci 851 (2007) 21-29
57. Tojo A., Welch W.J., Bremer V., Kimoto M., Kimura K., Omata M., et al. Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. Kidney Int 52 (1997) 1593-1601
58. Carello K.A., Whitesall S.E., Lloyd M.C., Billecke S.S., and D'Alecy L.G. Asymmetrical dimethylarginine plasma clearance persists after acute total nephrectomy in rats. Am J Physiol Heart Circ Physiol 290 (2006) H209-H216
59. G-dimethylarginine in the rabbit. Biochem J 154 (1976) 179-184
60. Baylis C. Nitric oxide deficiency in chronic kidney disease. Am J Physiol Renal Physiol 294 (2008) F1-F9
61. Xiao S., Wagner L., Schmidt R.J., and Baylis C. Circulating endothelial nitric oxide synthase inhibitory factor in some patients with chronic renal disease. Kidney Int 59 (2001) 1466-1472
62. Xiao S., wagner L., Mahaney J., and Baylis C. Uremic levels of urea inhibit l-arginine transport in cultured endothelial cells. Am J Physiol Renal Physiol 280 (2001) F989-F995
63. Hatzoglou M., Fernandez J., Yaman I., and Closs E. Regulation of cationic amino acid transport: the story of the CAT-1 transporter. Annu Rev Nutr 24 (2004) 377-399
64. Closs E.I. Expression, regulation and function of carrier proteins for cationic amino acids. Curr Opin Nephrol Hypertens 11 (2002) 99-107
65. Albritton L.M., Tseng L., Scadden D., and Cunningham J.M. A putative murine ecotropic retrovirus receptor gene encodes a multiple membrane-spanning protein and confers susceptibility to virus infection. Cell 57 (1989) 659-666
66. Aulak K.S., Liu J., Wu J., Hyatt S.L., Puppi M., Henning S.J., et al. Molecular sites of regulation of expression of the rat cationic amino acid transporter gene. J Biol Chem 271 (1996) 29799-29806
67. Yoshimoto T., Yoshimoto E., and Meruelo D. Enhanced gene expression of the murine ecotropic retroviral receptor and its human homolog in proliferating cells. J Virol 66 (1992) 4377-4381
68. Fernandez J., Lopez A.B., Wang C., Mishra R., Zhou L., Yaman I., et al. Transcriptional control of the arginine/lysine transporter, cat-1, by physiological stress. J Biol Chem 278 (2003) 50000-50009
69. Fernandez J., Yaman I., Mishra R., Merrick W.C., Snider M.D., Lamers W.H., et al. Internal ribosome entry site-mediated translation of a mammalian mRNA is regulated by amino acid availability. J Biol Chem 276 (2001) 12285-12291
70. Fernandez J., Bode B., Koromilas A., Diehl J.A., Krukovets I., Snider M.D., et al. Translation mediated by the internal ribosome entry site of the cat-1 mRNA is regulated by glucose availability in a PERK kinase-dependent manner. J Biol Chem 277 (2002) 11780-11787
71. Bhattacharyya S.N., Habermacher R., Martine U., Closs E.I., and Filipowicz W. Relief of microRNA-mediated translational repression in human cells subjected to stress. Cell 125 (2006) 1111-1124
72. Pillai R.S., Bhattacharyya S.N., Artus C.G., Zoller T., Cougot N., Basyuk E., et al. Inhibition of translational initiation by Let-7 MicroRNA in human cells. Science 309 (2005) 1573-1576
73. Chang J., Nicolas E., Marks D., Sander C., Lerro A., Buendia M.A., et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol 1 (2004) 106-113
74. Sobrevia L., Yudilevich D.L., and Mann G.E. Activation of A2-purinoceptors by adenosine stimulates l-arginine transport (system y+) and nitric oxide synthesis in human fetal endothelial cells. J Physiol 499 (1997) 135-140
75. Bogle R.G., Baydoun A.R., Pearson J.D., and Mann G.E. Regulation of l-arginine transport and nitric oxide release in superfused porcine aortic endothelial cells. J Physiol 490 (1996) 229-241
76. Flores C., Rojas S., Aguayo C., Parodi J., Mann G., Pearson J.D., et al. Rapid stimulation of l-arginine transport by d-glucose involves p42/44(mapk) and nitric oxide in human umbilical vein endothelium. Circ Res 92 (2003) 64-72
77. Gonzalez M., Flores C., Pearson J.D., Casanello P., and Sobrevia L. Cell signalling-mediating insulin increase of mRNA expression for cationic amino acid transporters-1 and -2 and membrane hyperpolarization in human umbilical vein endothelial cells. Pflugers Arch 448 (2004) 383-394
78. Liu J., and Hatzoglou M. Control of expression of the gene for arginine transporter Cat-1 in rat liver cells by glucocorticoids and insulin. Amino Acids 15 (1998) 321-337
79. Wu J.Y., Robinson D., Kung H.-J., and Hatzoglou M. Hormonal regulation of the gene for the type C ectropic retrovirus receptor in rat liver cells. J Virol 68 (1994) 1615-1623
80. Helle F., Hultstrom M., Skogstrand T., Palm F., and Iversen B.M. Angiotensin II-induced contraction is attenuated by nitric oxide in afferent arterioles from the nonclipped kidney in 2K1C. Am J Physiol Renal Physiol 296 (2009) F78-F86
81. Hultstrom M., Helle F., and Iversen B.M. AT1 receptor activation regulates the mRNA expression of CAT-1, CAT-2, Arginase-1 and DDAH-2 in preglomerular vessels from angiotensin II hypertensive rats. Am J Physiol Renal Physiol 297 (2009) F163-F168
82. Ookawauchi K., Saibara T., Yoshikawa T., Chun-Lin L., Hayashi Y., Hiroi M., et al. Characterization of cationic amino acid transporter and its gene expression in rat hepatic stellate cells in relation to nitric oxide production. J Hepatol 29 (1998) 923-932
83. Durante W., Liao L., Iftikhar I., Cheng K., and Schafer A.I. Platelet-derived growth factor regulates vascular smooth muscle cell proliferation by inducing cationic amino acid transporter gene expression. J Biol Chem 271 (1996) 11838-11843
84. Durante W., Liao L., Reyna S.V., Peyton K.J., and Schafer A.I. Transforming growth factor-beta(1) stimulates l-arginine transport and metabolism in vascular smooth muscle cells: role in polyamine and collagen synthesis. Circulation 103 (2001) 1121-1127
85. Schwartz I.F., Chernichovsky T., Hagin D., Ingbir M., Reshef R., Chernin G., et al. Differential regulation of l-arginine transporters (cationic amino acid transporter-1 and -2) by peroxynitrite in rat mesangial cells. Nephrol Dial Transplant 21 (2006) 3409-3414
86. Hattori Y., Kasai K., and Gross S.S. Cationic amino acid transporter gene expression in cultured vascular smooth muscle cells and in rats. Am J Physiol 276 (1999) H2020-H2028
87. Mittermayer F., Namiranian K., Pleiner J., Schaller G., and Wolzt M. Acute Escherichia coli endotoxaemia decreases the plasma l-arginine/asymmetrical dimethylarginine ratio in humans. Clin Sci (Lond) 106 (2004) 577-581
88. Siroen M.P., Teerlink T., Nijveldt R.J., Prins H.A., Richir M.C., and Van Leeuwen P.A. The clinical significance of asymmetric dimethylarginine. Annu Rev Nutr 26 (2006) 203-228
89. Nijveldt R.J., Teerlink T., van der Hoven B., Siroen M.P., Kuik D.J., Rauwerda J.A., et al. Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. Clin Nutr 22 (2003) 23-30
90. Nijveldt R.J., Teerlink T., and van Leeuwen P.A.M. The asymmetrical dimethylarginine (ADMA) multiple organ failure hypothesis. Clin Nutr 22 (2003) 99-104
91. Schwartz I.F., Schwartz D., Traskonov M., Chernichovsky T., Wollman Y., Gnessin E., et al. l-arginine transport is augmented through up-regulation of tubular CAT-2 mRNA in ischemic acute renal failure in rats. Kidney Int 62 (2002) 1700-1706
92. Zhang W.Z., Venardos K., Chin-Dusting J., and Kaye D.M. Adverse effects of cigarette smoke on NO bioavailability: role of arginine metabolism and oxidative stress. Hypertension 48 (2006) 278-285
93. Jin L., Caldwell R.B., Li-Masters T., and Caldwell R.W. Homocysteine induces endothelial dysfunction via inhibition of arginine transport. J Physiol Pharmacol 58 (2007) 191-206
94. Zhang W.Z., Venardos K., Finch S., and Kaye D.M. Detrimental effect of oxidized LDL on endothelial arginine metabolism and transportation. Int J Biochem Cell Biol 40 (2008) 920-928
95. Kaye D.M., Ahlers B.A., Autelitano D.J., and Chin-Dusting J.P. In vivo and in vitro evidence for impaired arginine transport in human heart failure. Circulation 102 (2000) 2707-2712
96. Schlaich M.P., Parnell M.M., Ahlers B.A., Finch S., Marshall T., Zhang W.Z., et al. Impaired l-arginine transport and endothelial function in hypertensive and genetically predisposed normotensive subjects. Circulation 110 (2004) 3680-3686
97. Schwartz I.F., Ayalon R., Chernichovski T., Reshef R., Chernin G., Weinstein T., et al. Arginine uptake is attenuated through modulation of cationic amino-acid transporter-1, in uremic rats. Kidney Int 69 (2006) 298-303
98. Levin-Iaina N., Schwartz I., Chernichovsky T., Davidovitch A., Iaina A., and Schwartz D. Tubular and glomerular l-arginine transport (uptake and transporters) and the nitric oxide synthases in ischemic acute renal failure (iARF) in streptozotocin-induced diabetic rats (STZ-DM). Renal Fail 29 (2007) 1031-1038
99. Yang Z., Venardos K., Jones E., Morris B.J., Chin-Dusting J., and Kaye D.M. Identification of a novel polymorphism in the 3′UTR of the l-arginine transporter gene SLC7A1: contribution to hypertension and endothelial dysfunction. Circulation 115 (2007) 1269-1274
100. Yang Z., and Kaye D.M. Mechanistic insights into the link between a polymorphism of the 3′UTR of the SLC7A1 gene and hypertension. Hum Mutat 30 (2009) 328-333
101. Teerlink T., Neele S.J.M., De Jong S., Netelenbos J.C., and Stehouwer C.D.A. Oestrogen replacement therapy lowers plasma levels of asymmetrical dimethylarginine in healthy postmenopausal women. Clin Sci 105 (2003) 67-71
102. Post M.S., Verhoeven M.O., van der Mooren M.J., Kenemans P., Stehouwer C.D.A., and Teerlink T. Effect of hormone replacement therapy on plasma levels of the cardiovascular risk factor asymmetric dimethylarginine: a radomized placebo controlled 12 week study in healthy early postmenopausal women. J Clin Endocrinol Metab 88 (2003) 4221-4226
103. Holden D.P., Cartwright J.E., Nussey S.S., and Whitley G. Estrogen stimulates dimethylarginine dimethylaminohydrolase activity and the metabolism of asymmetric dimethylarginine. Circulation 108 (2003) 1575-1580
104. Bunck MC, Giltay EJ, Diamant M, Gooren LJ, Teerlink T. Differential effects of cross-sex hormonal treatment on plasma asymmetric dimethylarginine (ADMA) in healthy male-to-female and female-to-male transsexuals. Atherosclerosis; in press.
105. Richir M.C., Bouwman R.H., Teerlink T., Siroen M.P., de Vries T.P., and Van Leeuwen P.A. The prominent role of the liver in the elimination of asymmetric dimethylarginine (ADMA) and the consequences of impaired hepatic function. JPEN J Parenter Enteral Nutr 32 (2008) 613-621
106. Busch M., Fleck C., Wolf G., and Stein G. Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease-possible candidates for paradoxical epidemiology?. Amino Acids 30 (2006) 225-232
107. Wang D., Strandgaard S., Iversen J., and Wilcox C.S. Asymmetric dimethylarginine, oxidative stress, and vascular nitric oxide synthase in essential hypertension. Am J Physiol Regul Integr Comp Physiol 296 (2009) R195-R200
108. Wang D., Strandgaard S., Borresen M.L., Luo Z., Connors S., Yan Q., et al. Asymmetric dimethylarginine and lipid peroxidation products in early autosomal dominant polycystic kidney disease. Am J Kidney Dis 51 (2008) 184-191
109. Lajer M., Tarnow L., Jorsal A., Teerlink T., Parving H.H., and Rossing P. Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care 31 (2008) 747-752
110. Horowitz J.D., and Heresztyn T. An overview of plasma concentrations of asymmetric dimethylarginine (ADMA) in health and disease and in clinical studies: methodological considerations. J Chromatogr B Analyt Technol Biomed Life Sci 851 (2007) 42-50
111. Jacobi J., Maas R., Cordasic N., Koch K., Schmieder R.E., Boger R.H., et al. Role of asymmetric dimethylarginine for angiotensin II-induced target organ damage in mice. Am J Physiol Heart Circ Physiol 294 (2008) H1058-H1066
112. Lin K.Y., Ito A., Asagami T., Tsao P.S., Adimoolam S., Kimoto M., et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 106 (2002) 987-992
113. Palm F., Buerk D.G., Carlsson P.O., Hansell P., and Liss P. Reduced nitric oxide concentration in the renal cortex of streptozotocin-induced diabetic rats: effects on renal oxygenation and microcirculation. Diabetes 54 (2005) 3282-3287
114. Palm F., Friederich M., Carlsson P.O., Hansell P., Teerlink T., and Liss P. Reduced nitric oxide in diabetic kidneys due to increased hepatic arginine metabolism: implications for renomedullary oxygen availability. Am J Physiol Renal Physiol 294 (2008) F30-F37
115. Ohnishi M., Wada A., Tsutamoto T., Fujii M., Matsumoto T., Yamamoto T., et al. Endothelin stimulates an endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine, in experimental heart failure. Clin Sci (Lond) 103 Suppl. 48 (2002) 241S-244S
116. Moesgaard S.G., Pedersen L.G., Teerlink T., Haggstrom J., and Pedersen H.D. Neurohormonal and circulatory effects of short-term treatment with enalapril and quinapril in dogs with asymptomatic mitral regurgitation. J Vet Intern Med 19 (2005) 712-719
117. Okubo K., Hayashi K., Wakino S., Matsuda H., Kubota E., Honda M., et al. Role of asymmetrical dimethylarginine in renal microvascular endothelial dysfunction in chronic renal failure with hypertension. Hypertens Res 28 (2005) 181-189
118. Pedersen L.G., Tarnow I., Olsen L.H., Teerlink T., and Pedersen H.D. Body size, but neither age nor asymptomatic mitral regurgitation, influences plasma concentrations of dimethylarginines in dogs. Res Vet Sci 80 (2006) 336-342
119. Masuda H., Goto M., Tamaoki S., and Azuma H. Accelerated intimal hyperplasia and increased endogenous inhibitors of NO synthesis in rabbits with alloxan-induced hyperglycaemia. Br J Pharmacol 126 (1999) 211-218
120. Cardounel A.J., and Zweier J.L. Endogenous methylarginines regulate neuronal nitric-oxide synthase and prevent excitotoxic injury. J Biol Chem 277 (2002) 33995-34002
121. Miyazaki H., Matsuoka H., Cooke J.P., Usui M., Ueda S., Okuda S., et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 99 (1999) 1141-1146
122. Surdacki A., Nowicki M., Sandmann J., Tsikas D., Boeger R.H., Bode-Boger S.M., et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 33 (1999) 652-658
123. Goonasekera C.D., Rees D.D., Woolard P., Frend A., Shah V., and Dillon M.J. Nitric oxide synthase inhibitors and hypertension in children and adolescents. J Hypertens 15 (1997) 901-909
124. G-dimethylarginine in human essential hypertension. Am J Hypertens 15 (2002) 590-593
125. MacAllister R., Rambausek M.H., Vallance P., Williams D., Hoffmann K.H., and Ritz E. Concentration of dimethyl-l-arginine in the plasma of patients with end-stage renal failure. Nephrol Dial Transplant 11 (1996) 2449-2452
126. Anderstam B., Katzarski K., and Bergström J. Serum levels of NG,NG-dimethyl-l-arginine, a potential endogenous nitric oxide inhibitor in dialysis patients. J Am Soc Nephrol 8 (1997) 1437-1442
127. Schmidt R.J., Domico J., Samsell L.S., Yokota S., Tracy T.S., Sorkin M.I., et al. Indices of activity of the nitric oxide system in hemodialysis patients. Am J Kidney Dis 34 (1999) 228-234
128. Tarnow L., Hovind P., Teerlink T., Stehouwer C.D., and Parving H.H. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care 27 (2004) 765-769
129. Altinova A.E., Arslan M., Sepici-Dincel A., Akturk M., Altan N., and Toruner F.B. Uncomplicated type 1 diabetes is associated with increased asymmetric dimethylarginine concentrations. J Clin Endocrinol Metab 92 (2007) 1881-1885
130. Asagami T., Abbasi F., Stuelinger M., Lamendola C., McLaughlin T., Cooke J.P., et al. Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism 51 (2003) 843-846
131. Abbasi F., Asagmi T., Cooke J.P., Lamendola C., McLaughlin T., Reaven G.M., et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 88 (2001) 1201-1203
132. Hanai K., Babazono T., Nyumura I., Toya K., Tanaka N., Tanaka M., et al. Asymmetric dimethylarginine is closely associated with the development and progression of nephropathy in patients with type 2 diabetes. Nephrol Dial Transplant 24 (2009) 1884-1888
133. Mittermayer F., Mayer B.X., Meyer A., Winzer C., Pacini G., Wagner O.F., et al. Circulating concentrations of asymmetrical dimethyl-l-arginine are increased in women with previous gestational diabetes. Diabetologia 45 (2002) 1372-1378
134. Xiong Y., Fu Y., Fu S., and Zhou H. Elevated levels of the serum endogenous inhibitor of nitric oxide synthase and metabolic control in rats with streptozotocin-induced diabetes. J Cardiovasc Pharmacol 42 (2003) 191-196
135. Xiong Y., Lei M., Fu S., and Fu Y. Effect of diabetic duration on serum concentrations of endogenous inhibitor of nitric oxide synthase in patients and rats with diabetes. Life Sci 77 (2005) 149-159
136. Chan N.N., and Chan J.C. Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome?. Diabetologia 45 (2002) 1609-1616
137. Stuhlinger M., Abbasi F., Chu J., Lamendola C., McLaughlin T., Cooke J.P., et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 287 (2002) 1420-1426
138. Sydow K., Mondon C.E., and Cooke J.P. Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA. Vasc Med 10 Suppl. 1 (2005) S35-S43
139. Ravani P., Tripepi G., Malberti F., Testa S., Mallamaci F., and Zoccali C. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 16 (2005) 2449-2455
140. Lund S.S., Tarnow L., Stehouwer C.D., Schalkwijk C.G., Teerlink T., Gram J., et al. Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. Eur J Endocrinol 158 (2008) 631-641
141. Ulu N., Schoemaker R.G., Henning R.H., Buikema H., Teerlink T., Zijlstra F.J., et al. Proteinuria-associated endothelial dysfunction is strain dependent. Am J Nephrol 30 (2009) 209-217
142. Sydow K., Schwedhelm E., Arakawa N., Bode-Boger S.M., Tsikas D., Hornig B., et al. ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of l-arginine and B vitamins. Cardiovasc Res 57 (2003) 244-252
143. Paiva H., Lehtimaki T., Laakso J., Ruokonen I., Rantalaiho V., Wirta O., et al. Plasma concentrations of asymmetric dimethyl arginine in type 2 diabetes associate with glycemic control and glomerular filtration rate but not risk factors of vasculopathy. Metabolism 52 (2003) 303-307
144. Eid H.M., Reims H., Arnesen H., Kjeldsen S.E., Lyberg T., and Seljeflot I. Decreased levels of asymmetric dimethylarginine during acute hyperinsulinemia. Metabolism 56 (2007) 464-469
145. Marcovecchio M.L., Widmer B., Dunger D.B., and Dalton R.N. Effect of acute variations of insulin and glucose on plasma concentrations of asymmetric dimethylarginine in young people with Type 1 diabetes. Clin Sci (Lond) 115 (2008) 361-369
146. Siroen M.P., Van Leeuwen P.A., Nijveldt R.J., Teerlink T., Wouters P.J., and Van den Berghe G. Modulation of asymmetric dimethylarginine in critically ill patients receiving intensive insulin treatment: a possible explanation of reduced morbidity and mortality?. Crit Care Med 33 (2005) 504-510
147. Simmons W.W., Closs E.I., Cunningham J.M., Smith T.W., and Kelly R.A. Cytokines and insulin induce cationic amino acid transporter (CAT) expression in cardiac myocytes. J Biol Chem 271 (1996) 11694-11702
148. Leiper J., and Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res 43 (1999) 542-548
149. Boger R.H., Vallance P., and Cooke J.P. Asymmetric dimethylarginine (ADMA): a key regulator of nitric oxide synthase. Atheroscler Suppl 4 (2003) 1-3
150. Druhan L.J., Forbes S.P., Pope A.J., Chen C.A., Zweier J.L., and Cardounel A.J. Regulation of eNOS-derived superoxide by endogenous methylarginines. Biochemistry 47 (2008) 7256-7263
151. Cardounel A.J., Xia Y., and Zweier J.L. Endogenous methylarginines modulate superoxide as well as nitric oxide generation from neuronal nitric-oxide synthase: differences in the effects of monomethyl- and dimethylarginines in the presence and absence of tetrahydrobiopterin. J Biol Chem 280 (2005) 7540-7549
152. Chen M.F., Xie X.M., Yang T.L., Wang Y.J., Zhang X.H., Luo B.L., et al. Role of asymmetric dimethylarginine in inflammatory reactions by angiotensin II. J Vasc Res 44 (2007) 391-402
153. Sakurada M., Shichiri M., Imamura M., Azuma H., and Hirata Y. Nitric oxide upregulates dimethylarginine dimethylaminohydrolase-2 via cyclic GMP induction in endothelial cells. Hypertension 52 (2008) 903-909
154. Wang D., Iversen J., Wilcox C.S., and Strandgaard S. Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal polycystic kidney disease. Kidney Int 64 (2003) 1381-1388
155. Aslam S., Santha T., Leone A., and Wilcox C.S. Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis. Kidney Int 70 (2006) 2109-2115
156. Lyons D., Roy S., Patel M., Benjamin N., and Swift C.G. Impaired nitric oxide-mediated vasodilatation and total body nitric oxide production in healthy old age. Clin Sci 93 (1997) 519-525
157. Cardounel A.J., Cui H., Samouilov A., Johnson W., Kearns P., Tsai A.L., et al. Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function. J Biol Chem 282 (2007) 879-887
158. Dayoub H., Achan V., Adimoolam S., Jacobi J., Stuehlinger M., Wang B., et al. Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis. Circulation 108 (2003) 3042-3047